Results 21 to 30 of about 76,328,651 (141)

Bioinformatic analysis reveals prognostic value and immunotherapy potential of Siglec-15 in laryngeal squamous cell carcinoma [PDF]

open access: yesHeliyon
Background: Laryngeal squamous cell carcinoma (LSCC) is the ultimate common malignant head and neck cancer with dismal prognosis. The expression pattern and clinical significance of Siglec-15 (Sialic acid-binding immunoglobulin-like lectin 15) in LSCC ...
Xiaoting Chen   +4 more
doaj   +2 more sources

Anti‐Siglec‐15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury‐Induced Immobilization in Rats [PDF]

open access: yesJBMR Plus, 2023
Rapid and extensive sublesional bone loss after spinal cord injury (SCI) is a difficult medical problem that has been refractory to available interventions except the antiresorptive agent denosumab (DMAB). While DMAB has shown some efficacy in inhibiting
Yuanzhen Peng   +13 more
doaj   +2 more sources

Development of a Novel Anti-Siglec-15 Antibody for Tumor Immunotherapy [PDF]

open access: yesImmunoTargets and Therapy
Qin Liu,1,* Lin Li,1,* Siji Nian,1 Xiaoke Sun,2 Xiyuan Guo,1 Chengwen Li,1 Zhihui Yang,3 Yingchun Ye,1 Qing Yuan1,4 1Public Center of Experimental Technology, The School of Basic Medical Sciences, Southwest Medical University, Luzhou ...
Liu Q   +8 more
doaj   +2 more sources

Killing two birds with one stone: Siglec-15 targeting integrated bioactive glasses hydrogel for treatment of breast cancer bone metastasis [PDF]

open access: yesMaterials Today Bio
Bone metastasis is a fatal consequence of breast cancer that occurs when patients fail to respond to conventional therapies and mainly result from a vicious cycle involving dysregulated bone homeostasis and uncontrolled tumor growth.
Chengkuan Liu   +6 more
doaj   +2 more sources

Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor [PDF]

open access: yesBone Research
DNAX-associated protein 12 kD size (DAP12) is a dominant immunoreceptor tyrosine-based activation motif (ITAM)-signaling adaptor that activates costimulatory signals essential for osteoclastogenesis.
Hideyuki Kobayashi   +11 more
doaj   +2 more sources

Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec‐15 axis in immune escape [PDF]

open access: yesCancer Communications
Background Metabolic reprograming and immune escape are two hallmarks of cancer. However, how metabolic disorders drive immune escape in head and neck squamous cell carcinoma (HNSCC) remains unclear.
Xin‐Yu Zhang   +7 more
doaj   +2 more sources

Long Noncoding RNA TUG1 Inhibits Tumor Progression through Regulating Siglec-15-Related Anti-Immune Activity in Hepatocellular Carcinoma

open access: yesJournal of Immunology Research, 2022
Background. Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death, and its biology remains poorly understood, especially in regards to the immunosuppression induced by immune checkpoints, such as Siglec-15.
Yanyi Ren   +4 more
doaj   +2 more sources

Development of an immunohistochemical assay for Siglec-15. [PDF]

open access: yesLab Invest, 2022
Siglec-15, a member of sialic-acid binding immunoglobulin type lectins, is normally expressed by myeloid cells and upregulated in some human cancers and represents a promising new target for immunotherapy.
Shafi S   +17 more
europepmc   +4 more sources

Transcriptional Regulation of Siglec-15 by ETS-1 and ETS-2 in Hepatocellular Carcinoma Cells. [PDF]

open access: yesInt J Mol Sci, 2023
Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) has been identified as a crucial immune suppressor in human cancers, comparable to programmed cell death 1 ligand (PD-L1).
Sheng K   +6 more
europepmc   +2 more sources

Anti-Tumor Activities of Anti-Siglec-15 Chimeric Heavy-Chain Antibodies. [PDF]

open access: yesInt J Mol Sci
Immune checkpoint inhibitors like programmed cell death 1 (PD-1) antibodies have revolutionized cancer treatment, but patient response rates remain limited.
Cheng K   +7 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy